ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
First Subject Dosed In Phase 1 Trial Evaluating INP105
americanpharmaceuticalreview
August 30, 2018Impel NeuroPharma announced the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-and-active controlled crossover study of their intranasal olanzapine product, INP105, dosed via Impel's proprietary Precision Olfactory Delivery,
Pharma Sources Insight July 2025
